Core Insights - Immunome, Inc. (IMNM) shares increased by 6% to close at $9.3, driven by higher trading volume compared to typical sessions, contrasting with a 0.1% gain over the past four weeks [1][2] Company Performance - The rise in stock price is linked to growing investor optimism regarding the development of varegacestat, which is in late-stage clinical studies for treating desmoid tumors, alongside other early-stage cancer therapies [2] - The company is projected to report a quarterly loss of $0.52 per share, reflecting a year-over-year decline of 6.1%, with expected revenues of $2.47 million, an increase of 4.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 1.9% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Immunome is categorized under the Zacks Medical - Biomedical and Genetics industry, where Nurix Therapeutics, Inc. (NRIX) also operates, closing 2.2% lower at $11.39, with a 9.5% return over the past month [5] - Nurix Therapeutics has an unchanged consensus EPS estimate of -$0.72 for the upcoming report, representing a year-over-year change of -1.4% [6]

Group 1 - Alpha Cognition Inc. (ACOG) is currently ranked 7 in the Zacks Sector Rank among 989 companies in the Medical group, indicating strong performance relative to peers [2] - ACOG has a Zacks Rank of 1 (Strong Buy), suggesting it is poised to outperform the broader market in the next one to three months [3] - Over the past three months, the Zacks Consensus Estimate for ACOG's full-year earnings has increased by 49.3%, reflecting improved analyst sentiment and a positive earnings outlook [4] Group 2 - Year-to-date, ACOG has gained approximately 58.4%, while the average performance of Medical group stocks has declined by about 3.7%, demonstrating ACOG's strong outperformance [4] - ACOG belongs to the Medical - Biomedical and Genetics industry, which includes 497 companies and is currently ranked 85 in the Zacks Industry Rank; this industry has seen an average loss of 3.4% this year, further highlighting ACOG's superior performance [6] - Astellas Pharma Inc. (ALPMY), another stock in the Medical sector, has a year-to-date return of 0.9% and a Zacks Rank of 1 (Strong Buy), with its EPS consensus estimate increasing by 15.2% over the past three months [5][6]

Core Viewpoint - Novavax has experienced a significant decline in stock performance, with a return of -10.9% over the past month, contrasting with the S&P 500's +5.2% and the Zacks Medical - Biomedical and Genetics industry's +0.9% [2] Earnings Estimates - For the current quarter, Novavax is projected to report a loss of $0.12 per share, reflecting a -112.1% change year-over-year, with the consensus earnings estimate for the fiscal year at $2.65, indicating a +315.5% change [5][6] - The consensus earnings estimate for the next fiscal year is $0.4, which represents a -84.8% change from the previous year [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $130.5 million, indicating a year-over-year decline of -68.6%. For the current fiscal year, the estimate is $1.07 billion (+56.8%), while for the next fiscal year, it is $516.45 million (-51.7%) [11] Last Reported Results and Surprise History - In the last reported quarter, Novavax achieved revenues of $666.66 million, a +610.3% year-over-year increase, with an EPS of $2.93 compared to -$1.05 a year ago. The revenue exceeded the Zacks Consensus Estimate by +215.04%, and the EPS surprise was +312.68% [12][13] Valuation - Novavax is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers, which suggests potential undervaluation [17]

Ginkgo Bioworks Holdings, Inc. (DNA) shares rallied 18.9% in the last trading session to close at $11.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 36.1% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the potential of Ginkgo’s proprietary cell programming platforms, Foundry and Codebase. The company offers R&D services ut ...

In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.09, marking a -1.42% move from the previous day. This change lagged the S&P 500's daily gain of 0.52%. Meanwhile, the Dow gained 0.63%, and the Nasdaq, a tech-heavy index, added 0.48%. Prior to today's trading, shares of the company had lost 20.6% lagged the Medical sector's gain of 1.88% and the S&P 500's gain of 4.27%.Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings discl ...

SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today provided an update on progress achieved in relation to three studies carried out with institutes of higher learning. The studies, each one year in length, were aimed ...

Company Performance - Adma Biologics closed at $18.16, reflecting a -1.3% change from the previous day, underperforming the S&P 500's gain of 0.52% [1] - The stock has decreased by 6.93% over the past month, while the Medical sector gained 3.5% and the S&P 500 increased by 5.95% [1] Upcoming Earnings - Adma Biologics is projected to report earnings of $0.14 per share, indicating a year-over-year growth of 7.69% [2] - The Zacks Consensus Estimate for revenue is $121.1 million, representing a 12.98% increase from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $0.61 per share and revenue at $505.8 million, showing increases of +24.49% and +18.61% respectively from the prior year [3] - Recent changes in analyst estimates reflect shifting business dynamics, with positive adjustments indicating optimism regarding business and profitability [3] Valuation Metrics - Adma Biologics has a Forward P/E ratio of 30.16, compared to the industry average of 19.05, suggesting it is trading at a premium [6] - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a current Zacks Industry Rank of 83 [6] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks delivering an average annual return of +25% since 1988 [5] - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a recent 8.27% decrease in the Consensus EPS estimate over the last 30 days [5]

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $5.03, down 6.85% from the previous trading session, underperforming the S&P 500's daily gain of 0.52% [1] - Over the past month, the stock has appreciated by 21.35%, outperforming the Medical sector's gain of 3.5% and the S&P 500's gain of 5.95% [1] Upcoming Earnings - The company is expected to report an EPS of -$0.34, which is a 15% increase from the prior-year quarter [2] - Quarterly revenue is projected to be $15.58 million, reflecting an 8.02% increase from the year-ago period [2] Full Year Estimates - For the full year, earnings are projected at -$1.34 per share and revenue at $74.95 million, showing increases of 20.71% and 27.38% respectively from the previous year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Recursion Pharmaceuticals are important as they indicate evolving short-term business trends [4] - Positive changes in estimates suggest analyst optimism regarding the company's business and profitability [4] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record of outperforming, with 1 rated stocks producing an average annual return of +25% since 1988 [6] - The Zacks Consensus EPS estimate for Recursion Pharmaceuticals has shifted 0.19% upward over the past month, and the company currently holds a Zacks Rank of 3 (Hold) [6] Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CVS Health (CVS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.CVS Health is a member of our Medical group, which includes 996 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 1 ...

Company Performance - Moderna's stock closed at $27.54, reflecting a +2.53% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.8% [1] - Over the past month, shares of Moderna have increased by 3.11%, while the Medical sector gained 3.12% and the S&P 500 gained 5.12% [1] Upcoming Earnings - Analysts expect Moderna to report an EPS of -$2.97, which is a 10.81% increase from the prior-year quarter [2] - The Zacks Consensus Estimate for revenue is projected at $130.15 million, down 46% from the same period last year [2] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict an EPS of -$9.81 and revenue of $2.08 billion, indicating changes of -10.6% and -35.83% respectively from the previous year [3] - Recent changes to analyst estimates for Moderna suggest a favorable outlook on the company's business health and profitability [3] Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Moderna, has a Zacks Industry Rank of 86, placing it in the top 35% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]